• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Avalon GloboCare Corp.

    10/20/23 4:18:23 PM ET
    $AVCO
    Building operators
    Real Estate
    Get the next $AVCO alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001630212
    Avalon Globocare Corp.
    GLOBAL TECHNOLOGIES CORP
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Avalon GloboCare Corp.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Avalon GloboCare Corp.
    Street Address 1 Street Address 2
    4400 ROUTE 9 SUITE 3100
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    FREEHOLD NEW JERSEY 07728 732-780-4400

    3. Related Persons

    Last Name First Name Middle Name
    Jin David K
    Street Address 1 Street Address 2
    4400 Route 9 South Suite 3100
    City State/Province/Country ZIP/PostalCode
    Freehold NEW JERSEY 07728
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chief Executive Officer
    Last Name First Name Middle Name
    Ingargiola Luisa
    Street Address 1 Street Address 2
    4400 Route 9 South Suite 3100
    City State/Province/Country ZIP/PostalCode
    Freehold NEW JERSEY 07728
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer

    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
    X $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
       Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2023-10-09    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    Convertible Debt

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Revere Securities LLC 14178
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    650 FIFTH AVENUE 35FTH FLOOR
    City State/Province/Country ZIP/Postal Code
    NEW YORK NEW YORK 10019
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    MASSACHUSETTS
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $700,000 USD
    or    Indefinite
    Total Amount Sold $700,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    2

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $53,200 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Avalon GloboCare Corp. /s/ Luisa Ingargolia Luisa Ingargolia Chief Financial Officer 2023-10-20

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $AVCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AVCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalon GloboCare Announces NASDAQ Ticker Symbol Change from "AVCO" to "ALBT"

      Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 Symbol Change Better Reflects Avalon's New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from "AVCO" to "ALBT" at the open of market trading on Thursday, November 10, 2022. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "Yesterday we announced a transformative acquisition of Laboratory Services MSO, LLC,

      11/9/22 4:00:00 PM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million

      Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company")(NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and

      11/8/22 9:10:00 AM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon Globocare to Present at the LD Micro Main Event XV on October 26th

      Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentation details:Event:LD Micro Main Event XVDate:Wednesday, October 26th, 2022Time:4:00 PM PT/ 7:00 PM ET Register to watch the virtual presentation here.Management will be available for one-on-one meetings

      10/19/22 9:00:00 AM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Tauzin W J

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/9/23 11:12:55 AM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 4 filed by Sanders Steven Andrew

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/9/23 11:11:22 AM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 4 filed by Stilley William B. Iii

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/8/23 4:45:24 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    SEC Filings

    See more
    • Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Avalon GloboCare Corp. (0001630212) (Filer)

      11/22/23 4:49:04 PM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 10-Q filed by Avalon GloboCare Corp.

      10-Q - Avalon GloboCare Corp. (0001630212) (Filer)

      11/14/23 4:30:53 PM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon GloboCare Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Avalon GloboCare Corp. (0001630212) (Filer)

      11/9/23 4:30:46 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy

      Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematol

      5/18/22 9:00:00 AM ET
      $AVCO
      Building operators
      Real Estate
    • Siyata Mobile Appoints Peter Goldstein as Chairman and Adds Seasoned Public Company Executive Luisa Ingargiola to Board of Directors

      VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today announces the appointment of Peter Goldstein, currently a Siyata Board member, as the Chairman of its Board of Directors. In addition, Luisa Ingargiola, who has extensive experience on public company boards and in the capital markets, has been appointed to the Board of Directors effective as of the shareholders meeting on February 23, 2021. “Peter’s many years in working with emerging growth, publicly traded companies is paramount to our asking him to

      2/9/21 10:30:49 AM ET
      $SYTA
      $AVCO
      $SOLO
      $UAVS
      Telecommunications Equipment
      Telecommunications
      Building operators
      Real Estate

    $AVCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Avalon GloboCare Corp. (Amendment)

      SC 13D/A - Avalon GloboCare Corp. (0001630212) (Subject)

      1/24/24 8:35:42 PM ET
      $AVCO
      Building operators
      Real Estate